Covidien’s Strategies For MIS: An Interview With Chris Barry
Executive Summary
Chris Barry, president of Advanced Surgical Technologies at Covidien, discusses the company’s growth, strategies for increasing MIS penetration, and future directions.
You may also be interested in...
MIS 2014, Part 2: Opportunities And Challenges
The increasing prevalence of MIS and the opportunity for greater MIS penetration in existing procedures translate into significant growth potential for the MIS products market in the years ahead. Despite some challenges, device manufacturers are driving growth in the market by targeting key procedures and geographies with new robotic surgery systems and robotic-like technologies designed to enable more complex procedures to be performed via an MIS approach.
Irish Eyes May Smile On Taxes, But Medtronic Says There’s More To Covidien Deal
The $42.9 billion Medtronic-Covidien deal is the largest pure medical device deal ever. It would move Medtronic’s corporate address to Ireland, with a lower tax rate, but executives emphasize negotiating power with hospitals, product synergies and emerging-market footprint, as well as new flexibility to use overseas cash, as core rationales for the deal.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.